Tandem Diabetes Care (TNDM) EBITDA (2013 - 2026)

Tandem Diabetes Care has reported EBITDA for 14 years, with the latest figure at -$20.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 83.71% year-over-year to -$20.9 million; the trailing twelve-month figure through Mar 2026 stood at -$89.6 million (up 51.01% YoY), and the FY2025 full-year result was -$197.2 million, down 98.48% from the prior year.
• EBITDA for Q1 2026 stood at -$20.9 million, down from -$164000.0 in the prior quarter.
• The five-year high for EBITDA was -$164000.0 in Q4 2025, with the low at -$128.5 million in Q1 2025.
• Historically, EBITDA has averaged -$37.2 million across 5 years, with a median of -$26.4 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 960.91% — and 2025, when it soared 96.76%.
• Tandem Diabetes Care's EBITDA stood at -$12.6 million in 2022, then slumped by 109.64% to -$26.4 million in 2023, then soared by 80.85% to -$5.1 million in 2024, then soared by 96.76% to -$164000.0 in 2025, then slumped by 12669.51% to -$20.9 million in 2026.
• The last three EBITDA figures came in at -$20.9 million (Q1 2026), -$164000.0 (Q4 2025), and -$19.7 million (Q3 2025), per Business Quant data.